Boston Scientific admits stent risks

September 7, 2006

The U.S.-based Boston Scientific Corp. has admitted there is an increased risk of blood clots caused by use of its drug-coated cardiac stent.

The company -- the leading stent seller in the nation -- says an analysis of clinical data reveals the increased risk of blood clots months after a stent is implanted, The Wall Street Journal reported, noting the announcement marks the first time any stent maker has acknowledged the heightened risk of side effects from using drug-coated stents.

Stents are small, wire-mesh tubes that are inserted into a blood vessel or other body structure to provide support and keep the structure open. The drugs used to coat some stents are designed to prevent growth of tissue after implantation.

The Journal said stent sales exceed $5 billion annually in a market dominated by Boston Scientific and Johnson & Johnson.

Boston Scientific, which has its headquarters in Natick, Mass., claims recent studies suggest both its Taxus brand of stent and J&J's Cypher stent present similar risks of late-occurring blood clots. J&J company officials, however, told the Journal they see no statistically significant risk of late thrombosis caused by their Cypher stents.

Copyright 2006 by United Press International

Explore further: Study reports progress in preventing bleeding in atrial fibrillation

Related Stories

Results from the tranform-oct study reported

November 7, 2016

Results from TRANSFORM-OCT, a prospective, randomized trial using optical coherence tomography (OCT) to evaluate strut coverage and neoatherosclerosis (NA) found that bioresorbable polymer-based drug-eluting stents (BP-EES) ...

Recommended for you

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.